<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445546</url>
  </required_header>
  <id_info>
    <org_study_id>28-291 ex15/16</org_study_id>
    <nct_id>NCT03445546</nct_id>
  </id_info>
  <brief_title>Platelet Function in Resuscitated Patients-2</brief_title>
  <official_title>Platelet Function in Resuscitated Patients-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approx. 65% of resuscitated patients at the intensive care unit for internal medicine are due
      to myocardial infarction. Almost all patients are initially diagnosed and treated in the cath
      lab. Therapy usually consists of one or more stent implantations. After implantation of a
      coronary stent, dual platelet inhibition is necessary for 12 months. Insufficient platelet
      inhibition causes an pronounced increase in risk of stent thrombosis. Therefore, secured
      inhibition and knowledge of the individual platelet function is valuable.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients after successful resuscitation associated to a myocardial infarction will be
      included into the study the morning after the index event. Patients get dual platelet
      inhibition using cangrelor as P2Y12 (purinergic G protein-coupled receptors-12) inhibitor
      plus acetylsalicylic acid (ASS). Patients are treated with therapeutic hypothermia according
      to the local Standard operating procedure for 24h and rewarming is performed within an
      additional 5 to 20h. Platelet function is measured every morning and ASS mediated as well as
      P2Y12 mediated platelet function inhibition is recorded. All relevant clinical data including
      APACHE (Acute Physiology and Chronic Health Evaluation) and SOFA (Sequential Organ Failure
      Assessment score) scores are collected.

      The degree of platelet inhibition over time (4 days) and differences between the three drugs
      tested will be evaluated by optical aggregometry and by using the commercial VerifyNow test
      system.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2016</start_date>
  <completion_date type="Anticipated">April 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet inhibition measured with optical aggregometry</measure>
    <time_frame>4 days</time_frame>
    <description>Light transmittance aggregometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of death and stent thrombosis</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>oral P2Y12 inhibition</arm_group_label>
    <description>Patients with cardiac arrest and myocardial infarction treated with oral P2Y12 Inhibitor (from the historic cohort of NCT02914795)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravenous P2Y12 inhibition</arm_group_label>
    <description>Patients with cardiac arrest and myocardial infarction treated with intravenous P2Y12 Inhibitor (cangrelor)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>diagnostic test of platelet function</intervention_name>
    <description>Light transmittance aggregometry and VerifyNow</description>
    <arm_group_label>oral P2Y12 inhibition</arm_group_label>
    <arm_group_label>intravenous P2Y12 inhibition</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients surviving the first night after resuscitation due to myocardial infarction
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Myocardial infarction

          -  dual platelet inhibition

          -  resuscitation

          -  therapeutic hypothermia

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk von Lewinski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dirk von Lewinski, MD</last_name>
    <phone>+4331638580684</phone>
    <email>dirk.von-lewinski@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dirk von Lewinski, MD</last_name>
    <phone>+436649636759</phone>
    <email>dirk.von-lewinski@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk von Lewinski, MD</last_name>
      <phone>+4331638580684</phone>
      <email>dirk.von-lewinbski@medunigraz.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <results_reference>
    <citation>Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA; CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009 Dec 10;361(24):2330-41. doi: 10.1056/NEJMoa0908629.</citation>
    <PMID>19915222</PMID>
  </results_reference>
  <results_reference>
    <citation>Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF, Shaburishvili T, Huber K, Prats J, Liu T, Harrington RA, Becker RC. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012 Jul;34(1):44-55. doi: 10.1007/s11239-012-0737-3.</citation>
    <PMID>22569899</PMID>
  </results_reference>
  <results_reference>
    <citation>White HD, Bhatt DL, Gibson CM, Hamm CW, Mahaffey KW, Price MJ, Steg PG, Stone GW, Cortese B, Wilensky M, Deliargyris EN, Liu T, Prats J, Harrington RA. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). JACC Cardiovasc Interv. 2015 Mar;8(3):424-433. doi: 10.1016/j.jcin.2014.09.025. Epub 2015 Feb 18.</citation>
    <PMID>25703887</PMID>
  </results_reference>
  <results_reference>
    <citation>Nolan JP, Soar J, Cariou A, Cronberg T, Moulaert VR, Deakin CD, Bottiger BW, Friberg H, Sunde K, Sandroni C. European Resuscitation Council and European Society of Intensive Care Medicine Guidelines for Post-resuscitation Care 2015: Section 5 of the European Resuscitation Council Guidelines for Resuscitation 2015. Resuscitation. 2015 Oct;95:202-22. doi: 10.1016/j.resuscitation.2015.07.018.</citation>
    <PMID>26477702</PMID>
  </results_reference>
  <results_reference>
    <citation>Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S; ESC Scientific Document Group . 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320. Epub 2015 Aug 29.</citation>
    <PMID>26320110</PMID>
  </results_reference>
  <results_reference>
    <citation>Nikolaou NI, Arntz HR, Bellou A, Beygui F, Bossaert LL, Cariou A; Initial management of acute coronary syndromes section Collaborator. European Resuscitation Council Guidelines for Resuscitation 2015 Section 8. Initial management of acute coronary syndromes. Resuscitation. 2015 Oct;95:264-77. doi: 10.1016/j.resuscitation.2015.07.030. Epub 2015 Oct 15.</citation>
    <PMID>26477416</PMID>
  </results_reference>
  <results_reference>
    <citation>Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Bl√∂mstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215. Epub 2012 Aug 24.</citation>
    <PMID>22922416</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Heart Arrest</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

